A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of sequential neoadjuvant
chemotherapy and bevacizumab (Avastin), before surgery and/or radiotherapy, in participants
with inflammatory or locally advanced operable breast cancer. Participants will receive
5-fluorouracil, epidoxorubicin and cyclophosphamide (FEC), followed by paclitaxel, given
concomitantly with bevacizumab. The anticipated time on study treatment is 3-12 months, and
the target sample size is <100 individuals.